A protracted class action against the Commonwealth Bank of Australia brought by borrowers who claimed they were forced to default on their commercial loans has finally settled, a court has heard.
A judge has ruled that a settlement offer made in a case can be adduced into evidence in a construction company’s suit against its former lawyers, finding that the offer was not covered by without penalty privilege.
The competition regulator has taken training provider Express Online Training to court for allegedly misleading consumers by promising they would only be charged for their online courses upon completion and that the courses could be finished in one day.
A judge has signed off on almost $7.5 million in fees billed by the law firm behind the pelvic mesh class action against Boston Scientific, eight months after he approved the device maker’s $105 million settlement.
Clive Palmer has lost his bid to overturn a council decision to reject his plan for a residential development at a Gold Coast flood plain, with a judge noting that would-be residents would be subject to the “adverse odours” of a nearby sewerage treatment plant.
AMP has agreed to pay $100 million to settle a class action by financial advisers over its buyer of last resort policy, after suffering a loss at trial.
A judge has ordered wealth manager Mercer Financial Advice to pay a $12 million penalty for “extremely serious” fees-for-no-service conduct and breaches of its fee disclosure obligations, in a case brought by the Australian Securities and Investments Commission. In the case, filed in June last year, ASIC alleged that Mercer charged 761 customers a total…
A franchise class action against United Petroleum has asked a court for leave to expand the class action to include a group of commission agents and to add the oil company’s parent as a third defendant.
ASIC has escaped an individual insolvency practitioner’s bid for indemnity costs in its failed case alleging illegal phoenix activity, with a judge finding the regulator did not unreasonably reject a settlement offer that would have netted it “a considerably better result” than it won at trial.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.